| Biomarker ID | 23 |
| PMID | 14654526 |
| Year | 2003 |
| Biomarker | XLKD1/LYVE1+CGA+ F2R/PAR1+ BCL-G |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Differentially Expressed |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(BCLG):-Mitochondrial pathway of apoptosis: antiapoptotic Bcl-2 family,p53 signaling pathway |
| Experiment | Patients with Relapse Vs Without Relapse |
| Type of Biomarker | Prognostic |
| Cohort | 7 patients with relapse, and 7 without relapse were included in the analysis |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | 100% |
| Level Of Significance | p<0.05 |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | Out of 291 genes, 46 genes showed differential expression, out of which a 4 gene panel was selected to differentiate b/w the patients who relapsed and those who did not. |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | LYVE1, CGA, F2R, BCLG |